vatalanib has been researched along with Kidney Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, AJ; Bitting, RL; Creel, PA; George, DJ; Healy, P; Hurwitz, HI; Morris, K; Nixon, AB; Starr, MD; Turnbull, J; Wood, SY | 1 |
| Alsop, DC; de Bazelaire, C; George, D; Michaelson, MD; Pedrosa, I; Rofsky, NM; Wang, Y | 1 |
| Allegrini, PR; Drevs, J; Esser, N; Fuxius, S; Hennig, J; Hugenschmidt, H; Konerding, MA; Marmé, D; Müller-Driver, R; Unger, C; Wittig, C; Wood, J | 1 |
| Alsop, DC; De Bazelaire, C; Duhamel, G; George, D; Michaelson, MD; Rofsky, NM | 1 |
| Bold, G; Buchdunger, E; Cozens, R; Drevs, J; Ferrari, S; Frei, J; Hofmann, F; Martiny-Baron, G; Menrad, A; Mestan, J; Mett, H; O'Reilly, T; Persohn, E; Rösel, J; Schirner, M; Schneider, MR; Schnell, C; Siemeister, G; Stover, D; Theuer, A; Thierauch, KH; Totzke, F; Towbin, H; Wenger, F; Wood, JM; Woods-Cook, K | 1 |
| Drevs, J; Hofmann, I; Hugenschmidt, H; Madjar, H; Marmé, D; Martiny-Baron, G; Müller, M; Unger, C; Wittig, C; Wood, J | 1 |
3 trial(s) available for vatalanib and Kidney Neoplasms
| Article | Year |
|---|---|
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Phthalazines; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2014 |
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Feasibility Studies; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neovascularization, Pathologic; Phthalazines; Pyridines; Regional Blood Flow | 2008 |
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Contrast Media; Feasibility Studies; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Spin Labels | 2005 |
3 other study(ies) available for vatalanib and Kidney Neoplasms
| Article | Year |
|---|---|
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow | 2002 |
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Carcinoma; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Hematopoiesis; Humans; Kidney Neoplasms; Leukocytes; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Platelet-Derived Growth Factor; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wound Healing | 2000 |
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cell Division; Cyclohexanes; Disease Models, Animal; Enzyme Inhibitors; Female; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Renal Circulation; Sesquiterpenes | 2000 |